148962-11-2

Basic information

• Product Name: 1H-Pyrazole-4-carbonitrile, 3-amino-5-[[4-(dimethylamino)phenyl]amino]-
• CAS NO: 148962-11-2
• Molecular Formula: C12H14N6
• Molecular Weight: 242.283
• Mol File: 148962-11-2.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 1H-Pyrazole-4-carbonitrile, 3-amino-5-[[4-(dimethylamino)phenyl]amino]-(CAS DataBase Reference)
• NIST Chemistry Reference: 1H-Pyrazole-4-carbonitrile, 3-amino-5-[[4-(dimethylamino)phenyl]amino]-(148962-11-2)
• EPA Substance Registry System: 1H-Pyrazole-4-carbonitrile, 3-amino-5-[[4-(dimethylamino)phenyl]amino]-(148962-11-2)

Safety Data

• Hazardous Substances Data: 148962-11-2(Hazardous Substances Data)

Usage

Chemical structure

A pyrazole derivative with a carbonitrile functional group and an amino group substituted with a benzene ring containing a dimethylamino group.

Explanation

The compound is composed of a pyrazole ring (a five-membered ring with one nitrogen atom) and a carbonitrile group (a cyano group, -C≡N). The amino group (-NH2) is attached to the benzene ring, which also contains a dimethylamino group (-N(CH3)2).

Explanation

The compound has been studied for its potential as a targeted therapy for certain diseases, including cancer, due to its ability to selectively bind to specific receptors or enzymes.

Explanation

The compound may have potential uses in organic synthesis and medicinal chemistry as a building block for the development of new drug candidates.

Explanation

Further research is necessary to fully understand the potential applications and safety of this compound, as its properties and effects on biological systems are not yet fully known.

Upstream product

• 2131-64-8 4-isothiocyanato-N,N-dimethylaniline 
• 99-98-9 4-amino-N,N-dimethylaniline 
• 196504-89-9 2-[(4-Dimethylamino-phenylamino)-methylsulfanyl-methylene]-malononitrile 
• 5147-80-8 [Bis(methylthio)methylene]malononitrile 

Relevant articles and documents

Pyrazolopyrimidines: Potent Inhibitors Targeting the Capsid of Rhino- and Enteroviruses

There are currently no drugs available for the treatment of enterovirus (EV)-induced acute and chronic diseases such as the common cold, meningitis, encephalitis, pneumonia, and myocarditis with or without consecutive dilated cardiomyopathy. Here, we report the discovery and characterization of pyrazolopyrimidines, a well-tolerated and potent class of novel EV inhibitors. The compounds inhibit the replication of a broad spectrum of EV in vitro with IC50 values between 0.04 and 0.64 μM for viruses resistant to pleconaril, a known capsid-binding inhibitor, without affecting cytochrome P450 enzyme activity. Using virological and genetics methods, the viral capsid was identified as the target of the most promising, orally bioavailable compound 3-(4-trifluoromethylphenyl)amino-6-phenylpyrazolo[3,4-d]pyrimidine-4-amine (OBR-5-340). Its prophylactic as well as therapeutic application was proved for coxsackievirus B3-induced chronic myocarditis in mice. The favorable pharmacokinetic, toxicological, and pharmacodynamics profile in mice renders OBR-5-340 a highly promising drug candidate, and the regulatory nonclinical program is ongoing. Curing the common cold! A cluster of pyrazolopyrimidines with potent broad-spectrum activity against enteroviruses was discovered. Extensive structure-property relationship analyses led to the identification of 3-(4-trifluoromethyl-phenyl)amino-6-phenylpyrazolo[3,4-d]pyrimidine-4-amine, shown to be a blocker of the viral capsid protein, as a lead compound for drug development with favorable physicochemical, pharmacokinetic, and toxicological properties.

Synthesis of new pyrazolo[1,5-a]pyrimidine derivatives via CT-complexation

-